Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

J. Voortman; T. Harada; R. P. Chang; J. K. Killian; M. Suuriniemi; W. I., Jr. Smith; P. S. Meltzer; M. Lucchi; Y. Wang; G. Giaccone

Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

J. Voortman
, T. Harada
, R. P. Chang
, J. K. Killian
, M. Suuriniemi
, W. I., Jr. Smith
, P. S. Meltzer
, M. Lucchi
, Y. Wang
, G. Giaccone

Research output: Contribution to journal › Article › Academic › peer-review

Original language	English
Pages (from-to)	833-840
Journal	Current pharmaceutical design
Volume	19
Issue number	5
Publication status	Published - Feb 2013

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

SDG 3 Good Health and Well-being

Keywords

c-Met
mutation
neuroendocrine tumor
tyrosine kinase inhibitor

Cite this

@article{3dc89a7fbc09465e88e33f6624531767,

title = "Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors",

keywords = "c-Met, mutation, neuroendocrine tumor, tyrosine kinase inhibitor",

author = "J. Voortman and T. Harada and Chang, \{R. P.\} and Killian, \{J. K.\} and M. Suuriniemi and Smith, \{W. I., Jr.\} and Meltzer, \{P. S.\} and M. Lucchi and Y. Wang and G. Giaccone",

year = "2013",

month = feb,

language = "English",

volume = "19",

pages = "833--840",

journal = "Current pharmaceutical design",

issn = "1381-6128",

publisher = "Bentham Science Publishers B.V.",

number = "5",

}

TY - JOUR

T1 - Detection and Therapeutic Implications of c-Met Mutations in Small Cell Lung Cancer and Neuroendocrine Tumors

AU - Voortman, J.

AU - Harada, T.

AU - Chang, R. P.

AU - Killian, J. K.

AU - Suuriniemi, M.

AU - Smith, W. I., Jr.

AU - Meltzer, P. S.

AU - Lucchi, M.

AU - Wang, Y.

AU - Giaccone, G.

PY - 2013/2

Y1 - 2013/2

KW - c-Met

KW - mutation

KW - neuroendocrine tumor

KW - tyrosine kinase inhibitor

M3 - Article

SN - 1381-6128

VL - 19

SP - 833

EP - 840

JO - Current pharmaceutical design

JF - Current pharmaceutical design

IS - 5

ER -